Table 2 Outcomes of the included studies
From: Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis
First author | Mortality | Survivors | Not discharged | Still on ECMO | Complications on ECMO | Days on ECMO* |
|---|---|---|---|---|---|---|
Alnababteh | 6 | 4 | 3 | NR | 3 mechanical 7 haemorrhagic 6 renal 4 pulmonary 2 infectious 3 metabolic 2 limb | 12.85 ± 6.04 |
Akhtar | 4 | 14 | 0 | 0 |  | 17.7 ± 9.4 |
Barbaro | 380 | 588 | 67 | 31 | 295 mechanical 69 neurologic 444 renal | 13.9 (7.8–23.3) |
Charlton | 16 | 18 | 0 | 0 | Â | Â |
Cousin | 16 | NR | NR | NR | 8 mechanical 27 haemorrhagic 4 neurologic 15 renal 2 pulmonary 4 infectious 3 limb | 10.67 ± 5.45 |
Falcoz | 6 | 10 | 1 | 0 | 7 mechanical 62 haemorrhagic 1 neurologic 12 renal 1 cardiovascular 3 pulmonary 10 infectious 1 others (thrombocytopenia) | 9 [0–16] |
Guihaire | 4 | 16 | 4 | 3 | 18 mechanical 1 neurologic 10 pulmonary 3 infectious 1 other (mesenteric ischemia) | 19.0 ± 10.1 |
Huette | 4 | 8 | 0 | 0 | 5 mechanical 3 hemorrhagic 8 renal 1 cardiovascular 4 pulmonary 10 infectious 3 others (2 liver failure, 1 HIT) | 12 (9–22) |
Jackel | 8 | 7 | 0 | 0 | Â | Â |
Jang | 10 | 4 | 5 | 2 | 5 neurologic 9 renal 1 cardiovascular 6 pulmomary | 17.27 ± 16.42 |
Jozwiak | 6 | 5 | 0 | 0 | Â | Â |
Le Breton | 2 | 11 | 0 | 0 | 2 mechanical 3 hemorrhagic 2 infectious | 14.53 ± 8.84 |
Masur | 5 | 1 | 6 | NR | 6 neurologic | 9.60 |
Mustafa | 6 | 29 | 5 | 2 | 10 pulmonary | 29.9 ± 3.6 |
Roedl | 13 | 7 | 0 | 0 | Â | Â |
Schmidt | 25 | 38 | 20 | 5 | 25 mechanical 45 hemorrhagic 5 neurologic 38 renal 11 cardiovascular 50 pulmonary 129 infectious 7 others (5 thrombocytopenia, 2 HIT) | 20 (10–40) |
Shih | 16 | 21 | 0 | 0 | Â | Â |
Takeda | 120 | NR | NR | NR | NA | 18.4 ± 15.2 |
Yang | 12 | 6 | 3 | 0 | 3 hemorrhagic 8 renal 8 cardiovascular 6 pulmonary 3 infectious | NR |
Zayat | 8 | 9 | 0 | 0 | Â | Â |
Zeng | 5 | NR | 7 | 4 | NA | 11.3 ± 7.8 |
Zhang | 14 | 29 | 0 | 0 | Â | Â |